{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:29Z","timestamp":1792081529210,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>On June 23, 2020, Prolia<jats:sup>\u00ae<\/jats:sup> (denosumab) was approved by the National Medical Products Administration (NMPA) in the People\u2019s Republic of China as the first monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk of fractures. Its brand name in Chinese is \u666e\u7f57\u529b, a transliteration from the English name \u201cProlia\u201d, which has an implied meaning of \u201cto give strength to everyone\u201d\u2014\u00a0a suitable name for a potent anti-resorptive therapy. The approval was supported by a novel marketing authorization application (MAA) that included data from Prolia\u2019s global clinical trial program establishing favorable efficacy and safety, augmented by results from a real-world evidence (RWE) study confirming the effectiveness and safety of Prolia in clinical practice within Taiwan and Hong Kong. Key constructs for this registration-quality RWE study included the fit-for-purpose assessment of data quality, methodology and quantitative assessment of potential biases, good practices of study conduct, and reproducibility of results. Using data from clinical practice in Taiwan and Hong Kong to evaluate the benefits versus risks of Prolia treatment in ethnic Chinese women with postmenopausal osteoporosis, the RWE study results for effectiveness were comparable to efficacy demonstrated in the global clinical trial program and results for safety were consistent with the incidence observed in global post-marketing safety studies. While RWE is often used to monitor postmarket safety of drug products, support health insurance coverage decisions, and inform clinicians on real-world use of medicines, it has not been widely used to support regulatory approval for new medicines in lieu of clinical bridging studies in countries where such studies are required. Well-conducted registrational RWE studies can play a pivotal role in complementing the totality of evidence presented in an MAA. The benefits of such an approach include avoiding the collection of additional placebo-controlled trial data in populations where adequate ethnic characterization of efficacy, effectiveness, and safety may already exist from postmarketing sources, and accelerate access for patients to innovative medicines in important regions. Here, we describe a regulatory case study of a novel MAA incorporating RWE that provided important evidence to confirm the benefit:risk of a new drug and facilitated a label expansion to a new patient population.<\/jats:p>","DOI":"10.1007\/s43441-021-00342-4","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T14:02:46Z","timestamp":1633960966000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Novel Case Study of the Use of Real-World Evidence to Support the Registration of an Osteoporosis Product in China"],"prefix":"10.1007","volume":"56","author":[{"given":"Neal E.","family":"Storm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff L.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy W.","family":"Critchlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Galson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"342_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.cct.2013.09.006","volume":"36","author":"R Singh","year":"2013","unstructured":"Singh R, Wang O. Clinical trials in \u201cemerging markets\u201d: Regulatory considerations and other factors. Contemp Clin Trials. 2013;36:711\u20138.","journal-title":"Contemp Clin Trials"},{"key":"342_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11657-018-0549-y","volume":"14","author":"F Yu","year":"2019","unstructured":"Yu F, Xia W. The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. Arch Osteoporos. 2019;14:32.","journal-title":"Arch Osteoporos"},{"key":"342_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401\u201319.","journal-title":"Nat Rev Drug Discov"},{"key":"342_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. for the FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"},{"key":"342_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"342_CR6","unstructured":"Zhang J, Wang, H, for the State Food and Drug Administration Center for Drug Evaluation. Considerations for Clinical Trials Evaluating the Treatment of Postmenopausal Women with Osteoporosis Drugs. July 2011. Record Number: Beijing ICP 09013725."},{"key":"342_CR7","unstructured":"European Medicines Agency. Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. Document Reference: CPMP\/EWP\/552\/95 Rev. 2. 16 November 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf."},{"key":"342_CR8","unstructured":"Covington & Burling LLP. Chinese Government Initiates Significant Drug and Device Regulatory Reforms. 6 November 2017. https:\/\/www.cov.com\/-\/media\/files\/corporate\/publications\/2017\/11\/chinese_government_initiates_significant_drug_and_device_regulatory_reforms.pdf."},{"key":"342_CR9","unstructured":"Taylor NP. Asia Regulatory Roundup: China Opens Door to Foreign Trial Data for Accelerated Approvals. 10 October 2017. https:\/\/www.raps.org\/regulatory-focus\u2122\/news-articles\/2017\/10\/asia-regulatory-roundup-china-opens-door-to-foreign-trial-data-for-accelerated-approvals-(10-octob."},{"key":"342_CR10","unstructured":"U.S Food and Drug Administration. Framework for FDA\u2019s Real-World Evidence Program. December 2018. https:\/\/www.fda.gov\/media\/120060\/download."},{"key":"342_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.bone.2011.08.007","volume":"49","author":"Y Kumagai","year":"2011","unstructured":"Kumagai Y, Hasunuma T, Padhi D. A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administratered subcutaneously to postemenopausal Japanese women. Bone. 2011;49:1101\u20137.","journal-title":"Bone"},{"key":"342_CR12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","volume":"23","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, et al. Dose-response study of denosumab on bone mineral density and bone turnover markets in Japanese postmenopausal women with osteoporosis. Osteoporos Int. 2012;23:1131\u201340.","journal-title":"Osteoporos Int"},{"key":"342_CR13","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99:2599\u2013607.","journal-title":"J Clin Endocrinol Metab"},{"key":"342_CR14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3349\/ymj.2016.57.4.905","volume":"57","author":"JM Koh","year":"2016","unstructured":"Koh JM, Chung DJ, Chung YS, et al. Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension. Yonsei Med J. 2016;57:905\u201314.","journal-title":"Yonsei Med J"},{"key":"342_CR15","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence: what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137.","journal-title":"N Engl J Med"},{"key":"342_CR16","doi-asserted-by":"publisher","first-page":"j5262","DOI":"10.1136\/bmj.j5262","volume":"360","author":"X Sun","year":"2018","unstructured":"Sun X, Tan J, Tang L, et al. Real world evidence: experience and lessons from China. BMJ. 2018;360:j5262.","journal-title":"BMJ"},{"key":"342_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","volume":"20","author":"M Berger","year":"2017","unstructured":"Berger M, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value Health. 2017;20:1003\u20138.","journal-title":"Value Health."},{"key":"342_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su C-C, Shao S-C, et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"key":"342_CR19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/jbmr.3448","volume":"33","author":"C-W Sing","year":"2018","unstructured":"Sing C-W, Wong AY, Kiel DP, et al. Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res. 2018;33:1422\u201334.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"342_CR20","first-page":"1","volume":"13","author":"ECC Lai","year":"2021","unstructured":"Lai ECC, Lin TC, Lange JL, Chen L, Wong I, Sing C-W, Cheung C-L, Shao S-C, Yang Y-HK. Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis. Archiv Int. 2021;13(1):1\u201310.","journal-title":"Archiv Int."},{"key":"342_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","volume":"85","author":"JC Lo","year":"2016","unstructured":"Lo JC, Hui RL, Grimsrud CD, et al. The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone. 2016;85:142\u20137.","journal-title":"Bone"},{"key":"342_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/pds.3477","volume":"22","author":"F Xue","year":"2013","unstructured":"Xue F, Ma H, Stehman-Breen C, et al. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia\u00ae (denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf. 2013;22:1107\u201314.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"342_CR23","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00198-014-2624-6","volume":"25","author":"T-C Lin","year":"2014","unstructured":"Lin T-C, Yang C-Y, Kao Yang Y-H, et al. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos Int. 2014;25:1503\u201311.","journal-title":"Osteoporos Int"},{"key":"342_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/clpt.2011.62","volume":"90","author":"T-C Lin","year":"2011","unstructured":"Lin T-C, Yang C-Y, Kao Yang Y-H, et al. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011;90:109\u201316.","journal-title":"Clin Pharmacol Ther"},{"key":"342_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pds.4295","volume":"26","author":"SV Wang","year":"2017","unstructured":"Wang SV, Schneeweiss S, Berger ML, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V.10. Pharmacoepidemiol Drug Saf. 2017;26:1018\u201332.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"342_CR26","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.clinthera.2020.03.006","volume":"42","author":"WR Bolislis","year":"2020","unstructured":"Bolislis WR, Fay M, Kuhler TC. Use of real-world data for new drug applications and line extensions. Clin Ther. 2020;42:926\u201338.","journal-title":"Clin Ther"},{"key":"342_CR27","unstructured":"NMPA-CDE. Guideline of Using Real-World Evidence to Support Drug Research & Development and Evaluation (Interim). National Medical Products Administration, Center for Drug Evaluation (NMPA-CDE). January 2020."}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-021-00342-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-021-00342-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-021-00342-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T22:49:38Z","timestamp":1640040578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-021-00342-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s43441-021-00342-4","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"9 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neal E. Storm is an Amgen employee and research collaborator with D.K. Kim International Center for Regulatory Science. Wen Chang, Tzu-Chieh Lin, Jeff L. Lange, Brian Bradbury, Cathy\u00a0W. Critchlow, and Steven K. Galson are employees of Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}